After years of a slow but steady rise in patenting activity at universities and research institutes across the globe, patenting rates have declined for the last two years, according to our 2022 biotech patenting Data Page
After years of a slow but steady rise in patenting activity at universities and research institutes across the globe, patenting rates have declined for the last two years, albeit modestly. Whether that involves a real downturn in activity, a backlog at the patent offices, or a shift from traditional technologies to newer ones not being captured in our searches is unclear. Notwithstanding this decline, patenting activity at the highest echelons of academia is essentially unchanged.
The same standalone universities — Stanford, Harvard, MIT — top the list as in the past few years, and their annual as well as average number of patents granted are essentially unchanged. Harvard has worked its way into the top spot for quantity and for impact, largely due to gene editing technologies.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The need for need-finding in medical education - Nature BiotechnologyThe paradigm of developing a novel technology and applying it to a clinically relevant problem may be dominant in academic medicine, but more emphasis is needed in identifying important clinical problems before looking for solutions.
Read more »
Targeted glioma therapy makes strides - Nature BiotechnologyIn Brief: Servier's successful phase 3 trial of vorasidenib in patients with a slow but usually fatal form of brain cancer, the first clinical breakthrough in the field for two decades, is likely to become a new standard of care
Read more »
San Diego biotech Heron Therapeutics cuts 25% of workers, second corporate restructuring in a yearThe biotechnology company — which makes cancer and pain-management therapies — has not reached profitability and its new management is taking actions to reserve cash
Read more »
Breakingviews - Biotech’s doldrums are a warning amid exuberanceBiotechnology stocks have a tendency for the overdramatic, but they often pick up on economic trends early. So it’s worrying that Danaher , a supplier for drug firms, cut its annual revenue forecast on Tuesday in part because biotech companies are conserving capital. The sector’s doldrums are a warning sign, despite the broader market shrugging off recession concerns.
Read more »
Goldman upgrades this biotech, sees the shares doublingThe firm's price target implies shares could rally 117%.
Read more »
Biotech Stocks Join AI-Fueled RallyShares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.
Read more »